InMed Pharmaceuticals (INM) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
InMed Pharmaceuticals has filed an international patent application for INM-901, a small molecule drug candidate aimed at treating neurodegenerative diseases like Alzheimer’s. The drug shows promise in reducing neuroinflammation and improving cognitive function, positioning it as a potentially significant advancement in treating these conditions.
For further insights into INM stock, check out TipRanks’ Stock Analysis page.